Mast cells, glia and neuroinflammation: partners in crime?

Summary

Glia and microglia in particular elaborate pro-inflammatory molecules that play key roles in central nervous system (CNS) disorders from neuropathic pain and epilepsy to neurodegenerative diseases. Microglia respond also to pro-inflammatory signals released from other non-neuronal cells, mainly those of immune origin such as mast cells. The latter are found in most tissues, are CNS resident, and traverse the blood–spinal cord and blood–brain barriers when barrier compromise results from CNS pathology. Growing evidence of mast cell–glia communication opens new perspectives for the development of therapies targeting neuroinflammation by differentially modulating activation of non-neuronal cells that normally control neuronal sensitization – both peripherally and centrally. Mast cells and glia possess endogenous homeostatic mechanisms/molecules that can be up-regulated as a result of tissue damage or stimulation of inflammatory responses. Such molecules include the N-acylethanolamine family. One such member, N-palmitoylethanolamine is proposed to have a key role in maintenance of cellular homeostasis in the face of external stressors provoking, for example, inflammation. N-Palmitoylethanolamine has proven efficacious in mast-cell-mediated experimental models of acute and neurogenic inflammation. This review will provide an overview of recent progress relating to the pathobiology of neuroinflammation, the role of microglia, neuroimmune interactions involving mast cells and the possibility that mast cell–microglia cross-talk contributes to the exacerbation of acute symptoms of chronic neurodegenerative disease and accelerates disease progression, as well as promoting pain transmission pathways. We will conclude by considering the therapeutic potential of treating systemic inflammation or blockade of signalling pathways from the periphery to the brain in such settings.

Keywords: mast cells; microglia; neurodegeneration; neuroinflammation; neuroprotection; palmitoylethanolamide.
**Introduction**

Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process. However, when prolonged, inflammation overrides the bounds of physiological control and eventually becomes destructive. Inflammation increasingly surfaces as a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury and perhaps even neuropsychiatric disorders. A plethora of pro-inflammatory cytokines, eicosanoids and other immune neurotoxins, have been found in cerebrospinal fluid and/or affected brain regions of patients with neurodegenerative disorders. Consider also that nuclear factor-κB, a requisite transcription factor for most pro-inflammatory molecules, is activated in the substantia nigra pars compacta of Parkinson’s disease patients and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice and monkeys, and its selective inhibition protects dopaminergic neurons from MPTP toxicity. It is intriguing to note that neuroinflammation may also raise the brain’s sensitivity to stress. Indeed, a recently published study by Zhang et al. reports that inflammation-activated signalling pathways in the brain’s hypothalamus control the production of ageing-related hormones. This finding provides a link between inflammation, stress responses and ageing. Inflammation therefore constitutes an important target for neuronal protection in neurodegenerative disorders and neuropathic pain, the latter resulting from damage or disease affecting the somatosensory system.

Recognition that there is extensive communication between the immune system and the central nervous system (CNS) is, no doubt, one of the more fundamental advances in neuroscience in recent times. Inflammatory cytokines occupy a key niche in this network, regulating host responses to infection, inflammation, stress and trauma. Glial cell activation has been implicated in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, cerebral ischaemia, multiple sclerosis and motor neuron disease, and possibly schizophrenia and depression. Microglia-mediated neuroinflammatory processes are also proposed to compromise healthy brain aging. Found to accumulate at sites of injury or plaques in neurodegenerative CNS diseases, microglia scavenge dead cells and secrete neuron survival factors; the latter may have beneficial effects in the recovery of injured CNS. However, inappropriate and prolonged activation of glia can cause autoimmune responses leading to brain injury and neuronal cell death. Glia provide a link also between neuroinflammation and neuropathic pain; microglia, in particular, show increased activity in multiple pain-processing pathways in response to peripheral injury. Systemic inflammation gives rise to signals that communicate with the brain and leads to changes in metabolism and behaviour – including the expression of a pro-inflammatory phenotype by microglia. It has been proposed that in multiple chronic disease states, and in ageing, microglia are primed by previous pathology, or by genetic predisposition, to respond more vigorously to subsequent inflammatory stimulation, so transforming an adaptive CNS inflammatory response to systemic inflammation, into one with deleterious consequences. It therefore goes without saying that delineating the signalling pathways underlying glial cell activation is crucial in the design of agents capable of antagonizing such signalling steps – which may translate into therapeutic benefit for neurodegenerative disorders and neuropathic pain.

Although it is widely accepted that glial cell activation contributes to neuropathology, one must not forget that microglia and astrocytes also respond to pro-inflammatory signals released from other cells of immune origin. In this view, mast cells represent a potentially important (and underappreciated) peripheral immune signalling link to the brain in an inflammatory setting (Fig. 1). Mast cells share similarities with basophil granulocytes in blood, although the former are likely generated by different precursor cells in the bone marrow. In contrast to basophils, mast cells circulate in an immature form until choosing a tissue site to settle – which probably determines their precise characteristics. These effector cells of the innate immune system are present in most tissues in the vicinity of blood vessels, particularly near surfaces exposed to the environment. Mast cells participate in innate host defence reactions, occur in peripheral tissues innervated by small calibre sensory nerve fibres and within the endoneurial compartment of peripheral nerves, and in meninges and cerebral blood vessels. During development they enter the brain by way of penetrating blood vessels, with which they remain associated. Mast cells can move through the blood–brain barrier of normal brain, but may also traverse the blood–spinal cord barrier and blood–brain barrier when compromised by disease. Interestingly, they are capable of phagocytosis and antigen presentation, and can modulate the adaptive immune response (Box 1).

Mast cells produce a vast array of mediators, which include biogenic amines, cytokines, enzymes, lipid metabolites, ATP, neuropeptides, growth factors and nitric oxide (Table 1). Because of their heterogeneity, however, no single mast cell makes all of these. By nature of their immune regulatory role they participate in IgE switching by B cells, and the release of chemoattractants that recruit eosinophils and monocytes. Certain disease states, like those involving autoimmune demyelination are accompanied by an increased absolute number of mast cells within the CNS, as well as those undergoing degranulation. Mast cell tryptase is elevated in the cerebrospinal fluid of patients with multiple sclerosis. At the other end of the equation, activated mast cells can provoke demyelination and induce apoptotic oligoden-
Enzymes
rides
et al.
sis, at least in a subgroup of these patients. Inflammation and autism-spectrum disorders pathogenesis
allergic triggers can lead to release of pro-inflammatory
316
and astrocytes, together with elements of the peripheral
strongly dependent on Schwann cells, spinal microglia and astrocyte cell death.31 Brain mast cells might even 'bridge' the immune system and anxiety-like behaviour.32 Theoharides et al.,33 have suggested that perinatal mast cell activation by infectious, stress-related, environmental or allergic triggers can lead to release of pro-inflammatory and neurotoxic molecules, so contributing to brain inflammation and autism-spectrum disorders pathogenesis, at least in a subgroup of these patients.

Microglia, mast cells and nervous system disease

Neuropathic pain
Persistent pain represents a substantial and growing unmet medical need, affecting nearly half of people seeking medical care in the USA alone. Among all types of chronic pain, neuropathic pain stands out: this is pain resulting from damage, degeneration or dysfunction of the sensory nervous system, and remains largely untreatable. Central neuropathic pain is found in spinal cord injury, multiple sclerosis and some strokes, whereas the common causes of painful peripheral neuropathies are diabetes and other metabolic conditions. Neuropathic pain is common in cancer as a direct result of cancer on peripheral nerves or as a side effect of chemotherapy. The triggering and maintenance of neuropathic pain states is strongly dependent on Schwann cells, spinal microglia and astrocytes, together with elements of the peripheral immune system.34 Release of interleukin-1β (IL-1β) from spinal microglia as a consequence of inflammation/injury may, by engaging its receptor, induce phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit to strengthen painful signal transmission.35 Under pathological conditions dorsal horn microglia become activated and show up-regulated expression of purinergic receptors,36,37 whose inhibition or deletion strongly attenuates neuropathic pain.36–38

Upon degranulation, mast cells release algogenic (from the Greek 'algos' for pain) substances which activate or sensitize nociceptors, thereby contributing directly to neuropathic pain.39 Nerve-resident peripheral nerve mast cells represent the first line of activation at the point of damage and facilitate recruitment of neutrophils and macrophages.40 Mast cell degranulation activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity,41 possibly mediated by a sensitizing effect of histamine on nociceptors. Rapid release of nerve growth factor from mast cells also produces sensitization of nociceptors via the latter’s high-affinity nerve growth factor-trkA receptors (and indirectly via other peripheral cell types).42 Interestingly, mast cells themselves respond to nerve growth factor, in a paracrine/autocrine fashion.43 These events promote the recruitment of T cells, which reinforce and maintain inflammatory reactions. The released mediators/factors can induce activity in axons and/or undergo retrograde transport to the cell body of dorsal root ganglion neurons, thereby affecting gene expression. Further, mast cells may enhance recruitment of other key immune cell types which, in turn, release pro-nociceptive mediators, such as IL-6.44 Systemic glucocorticoid therapy reduces pain and the number of tumour necrosis factor-α (TNF-α)-positive mast cells in rats with chronic constrictive injury, strengthening a role for mast cells in chronic pain states.45 Mast cells are also important mediators of chronic visceral pain.46

Ischaemia and traumatic brain injury
Stroke and traumatic brain injury are characterized by an inflammatory response in which microglia activation and macrophage/neutrophil infiltration are important elements.47 Left unchecked, this can ultimately lead to secondary injury. Yet, in certain instances attenuation of microglial activation can be beneficial.48 Considerable efforts have been directed also to inhibiting the consequences of blood-borne neutrophil and phagocyte infiltration in ischaemia. In contrast, less emphasis has been placed on brain-resident cell types able to mount an immediate host response in the cerebral parenchyma and meninges, for example, mast cells.49 Analogous to peripheral nerve damage – and contrary to what was long believed50 – mast cell activation is the ‘first responder’ in this injury.51 Although CNS microglia/macrophages and endothelial

Table 1. Mast cell mediators

<table>
<thead>
<tr>
<th>Biogenic amines</th>
<th>Biogenic amines [histamine (2–5 pg/cell), serotonin]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokines</td>
<td>Interleukins 1–6</td>
</tr>
<tr>
<td></td>
<td>Leukaemia inhibitory factor</td>
</tr>
<tr>
<td></td>
<td>Tumour necrosis factor-α</td>
</tr>
<tr>
<td></td>
<td>Interferon-γ</td>
</tr>
<tr>
<td></td>
<td>Transforming growth factor-β</td>
</tr>
<tr>
<td></td>
<td>Granulocyte-macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>Enzymes</td>
<td>Acid hydrolases</td>
</tr>
<tr>
<td></td>
<td>Chymase</td>
</tr>
<tr>
<td></td>
<td>Phospholipases</td>
</tr>
<tr>
<td></td>
<td>Rat mast-cell protease I and II</td>
</tr>
<tr>
<td></td>
<td>Trypsin</td>
</tr>
<tr>
<td>Lipid metabolites</td>
<td>Prostaglandin D_2</td>
</tr>
<tr>
<td></td>
<td>Leukotriene C_4</td>
</tr>
<tr>
<td></td>
<td>Platelet-activating factor</td>
</tr>
<tr>
<td>Other bioactive molecules</td>
<td>Neuropeptides (e.g. vasoactive intestinal peptide, substance P)</td>
</tr>
<tr>
<td></td>
<td>Proteoglycans, mainly heparin (active as an anticoagulant)</td>
</tr>
<tr>
<td></td>
<td>Nerve growth factor</td>
</tr>
<tr>
<td></td>
<td>ATP</td>
</tr>
<tr>
<td></td>
<td>Nitric oxide</td>
</tr>
</tbody>
</table>

© 2013 John Wiley & Sons Ltd, *Immunology*, 141, 314–327
Mast cells produce TNF-\(\alpha\) in response to stimuli, mast cells are ‘primed’ to initiate acute inflammation with their stores of pre-formed TNF-\(\alpha\).\(^{52}\) Treatment with mast cell-stabilizing agents limits the brain damage caused by perinatal hypoxia–ischaemia and transient focal ischaemia.\(^{51,53,54}\)

Given their complement of vasoactive and matrix-degrading components like histamine, and proteases able to activate matrix metalloproteinases, mast cells are an early response element in the regulation of acute blood–brain barrier changes after cerebral ischaemia and haemorrhage.\(^{55}\) By regulating acute microvascular gelatinase activation, cerebral mast cells can effect blood–brain barrier disruption following transient cerebral ischaemia.\(^{56}\)

### Chronic neurodegenerative diseases

Microglia are activated in response to a number of different pathological states within the CNS including neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and AIDS dementia complex. There is a vast literature on this facet of neuroinflammation that is beyond the scope of this article. The reader is referred to several excellent recent reviews.\(^{57,58}\) In the case of Parkinson’s disease, the oxidative stress response by microglial cells, most notably the activity of the enzyme NADPH oxidase, appears to play a central role in the ensuing pathology.\(^{59}\)

The case for mast cells, while somewhat analogous, depends to a greater extent on the specific disease. In patients with multiple sclerosis, especially in chronic active plaques, mast cells have been noted generally clustered around venules and capillaries.\(^{60}\) Mast cell-associated gene transcripts (e.g. tryptase) are also present in multiple sclerosis plaques, whereas mast cell mediators such as tryptase and histamine have been found in cerebrospinal fluid of multiple sclerosis patients, with levels rising during relapses.\(^{29,61}\) In mouse experimental autoimmune encephalomyelitis models of multiple sclerosis, however, there is no clear evidence whether the mast cell effects on experimental autoimmune encephalomyelitis development depend on mouse strain, immunization protocol or type and severity of disease.\(^{62}\) A role for mast cells in Alzheimer’s disease pathogenesis remains to be established, although one report claimed that fibrillar amyloid \(\beta\)-peptides trigger CD47-dependent mast cell secretory and phagocytic responses.\(^{63}\) For Parkinson’s disease, there is no clear evidence to support a relationship between brain mast cells and Parkinson’s disease. As this concerns mast cells and motor neuron disease, this point will be discussed separately below.

### Mast cells and ALS: at the crossroads?

Amyotrophic lateral sclerosis, also known as Charcot’s or Lou Gehrig’s disease, is the most prevalent type of motor neuron disease, affecting around 4–6 per 100 000. ALS is characterized by a progressive dysfunction and degeneration of both upper motor neurons comprising the corticospinal tract, and lower motor neurons arising from the brainstem nuclei and ventral roots of the spinal cord. Neuroinflammation is now established as an important aspect of pathology in ALS.\(^{64}\) There is a marked activation or proliferation of both microglia and astrocytes at specific disease stages in mouse models of ALS\(^{65}\) and in humans \textit{in vivo}.\(^{66}\) There is also compelling evidence indicating impairment of all neurovascular unit components including the blood–brain and blood–spinal cord barriers in both patients and animal models of ALS.\(^{67}\)

As discussed earlier, mast cells participate in innate host defence reactions, and orchestrate neuroinflammatory processes. Meningeal mast cells contain preformed TNF-\(\alpha\) (the only cell type to do so) and vasoactive mediators, which are able to regulate blood–brain barrier\(^{56}\) and blood–spinal cord barrier function and facilitate the entry of lymphocytes, neutrophils and mast cells themselves\(^{68}\) when the barrier is compromised as a result of CNS pathology, e.g. in ischaemic stroke and ALS, respectively. Indeed, degranulating\(^{70}\) and IL-17-expressing mast cells\(^{68}\) have been observed in the spinal cord of ALS patients, and serum levels of this cytokine are reported to correlate with the duration and severity of the disease.\(^{68}\)

An interaction between mast cells and T regulatory lymphocytes can lead to increased IL-6 production by the former,\(^{71}\) in turn promoting the activity of T helper type 17 lymphocytes.\(^{72}\) Moreover, IL-15 and IL-12 are elevated in the serum and cerebrospinal fluid of patients with ALS.\(^{73}\) Interleukin-15 is a mast cell chemoattractant\(^{74}\) (potentially contributing to mast cell recruitment in inflammatory responses), while mast cells are an important source of IL-12.\(^{75}\) Pathogen-associated molecular patterns (PAMPs) are molecules associated with groups of pathogens that are recognized by cells of the innate immune system. One important class of PAMP receptors is the transmembrane Toll-like receptors (TLRs). Interleukin-12 up-regulates expression of mast cell TLR2/TLR4\(^{76}\) and proteinase-activated receptor-2,\(^{77}\) emerging targets for neuroinflammation.\(^{78}\)

Functional TLR2 and TLR4 expressed by mast cells and microglia respond to molecules called damage-associated molecular patterns, one being the high mobility group Box 1 protein found elevated in the spinal cord of ALS patients.\(^{79}\) Likewise, microglia-released IL-6 and CCL5 could, conceivably affect surface TLR2 and TLR4 expression on mast cells,\(^{80}\) resulting in the up-regulation of numerous chemokines to induce a pro-inflammatory profile in microglia.\(^{81}\) Given that ALS patients frequently experience neuropathic pain, and that a transgenic mouse ALS model develops peripheral nerve inflammation,\(^{82}\) one might ask whether or not mast cells play a role here, as well.
Activated microglia elaborate a potentially lethal cocktail of compounds capable of damaging neurons, oligodendrocytes or extracellular matrix molecules, and depletion or blockade of microglia and macrophages prevents disease progression. Microglia/macrophages, however, may deliver trophic factors, and support myelin regeneration by phagocytic removal of obstructive myelin debris or through activation and recruitment of endogenous oligodendrocyte precursor cells to the lesion site. Microglia are found adjacent to amyloid deposits, and anti-inflammatory drugs that suppress the inflammatory response in microglia attenuate symptoms in a mouse model of Alzheimer’s disease. Yet, in one study reducing or ablating resident microglia failed to alter amyloid plaque load in transgenic mouse models of Alzheimer’s disease. Further, deleting the microglial chemokine receptor CCR2 (which mediates the accumulation of mononuclear phagocytes at sites of inflammation) accelerated early disease progression and impaired microglial accumulation in an Alzheimer’s disease mouse model. Microglia activation via TLR4 signalling appears able to reduce, to some extent, Aβ deposits and preserve cognitive functions from Aβ-mediated neurotoxicity. However, prolonged activation of microglia is likely to result in a pro-inflammatory state. This idea is borne out in a newly published study in which the authors used monophosphoryl lipid A (MPL), a lipopolysaccharide-derived TLR4 agonist that exhibits unique immunomodulatory properties at doses that are non-pyrogenic. Repeated systemic injections of MPL, but not lipopolysaccharide, significantly improved Alzheimer’s disease mouse models. Treatment with MPL led to a significant reduction in Aβ load in the brains of these mice, as well as to enhanced cognitive function. MPL induced a potent phagocytic response by microglia while triggering only a moderate inflammatory reaction.

As discussed earlier, acute CNS injuries are marked by a prolonged inflammatory response involving microglial activation and infiltration of macrophages and neutrophils.
As an autocrine/paracrine factor for mast cells, and ATP binding to P2 receptors may stimulate release of IL-33 from microglia pre-activated (‘primed’) with PAMPs via TLRs. Interleukin-33 can induce mast cells to secrete IL-6, IL-13 and CCL2 – in turn modulating microglia activity. Other examples include mast cell tryptase cleavage/activation of proteinase-activated receptor 2 on microglia (resulting in P2X4 receptor up-regulation and brain-derived neurotrophic factor release), while microglia-derived IL-6 and TNF-α up-regulate mast cell expression of proteinase-activated receptor 2, resulting in mast cell activation and TNF-α release. Elements of the complement system are also potential participants in this communication network, as the receptor for the chemoattractant C5a is markedly up-regulated on reactive astrocytes and microglia in inflamed CNS tissue. C5a peptide is released in neuroinflammation, and there is cross-talk between C5a and TLR4; mast cell C5a receptor is up-regulated upon activation, and C5a receptor is a strong mast cell chemoattractant signal towards C5a peptide. These last findings point to an additional element whereby microglia and mast cells may work in concert to promote neuroinflammation (Table 2).

**Taping endogenous mechanisms as a therapeutic approach to neuroinflammation**

Targeting microglial and mast cell activation is emerging as a promising avenue for neuropathic pain, as well as agents that inhibit neurotoxic glial cell activation. Given the dangers that neuroinflammation poses to the organism, it would not be surprising if Nature has endowed the body with the capacity for self-defence. Indeed, we now recognize the existence of molecules involved in endogenous protective mechanisms that are activated following different types of tissue damage or stimulation of inflammatory responses and nociceptive fibres. For example, chronic inflammatory processes such as those sustaining neuropathic pain may be counteracted by a programme of resolution that includes the production of lipid mediators able to switch off inflammation. Chronic inflammatory conditions may lower the levels or actions of these molecules; conceivably, administration of such lipid mediators might provide an avenue ‘to commandeer nature’s own anti-inflammatory mechanisms and induce a “dominant” program of resolution’. One interesting class of such natural mediators comprises the N-acylthanolamines (NAEs), which are composed of a fatty acid and ethanolamine – the so-called fatty acid ethanolamines. Principal fatty acid ethanolamine family members include the endocannabinoid N-arachidonoyl-ethanolamine (anandamide) and its congeners N-stearoyl-ethanolamine, N-oleylethanolamine and N-palmitoyl...
lethanolamine (PEA, or palmitoylethanolamide). PEA and its congeners are formed from N-acylated phosphatidylethanolamine (NAPE) by several enzymatic pathways, the principal one involving a membrane-associated NAPE-phospholipase D which generates the respective NAE and phosphatidic acid (Fig. 2). This

Table 2. Potential avenues of mast cell–glia communication

<table>
<thead>
<tr>
<th>Effector</th>
<th>Biological actions</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR2, TLR4</td>
<td>Microglial release of IL-6 and CCL5 affects surface expression of TLR2/TLR4 on mast cells</td>
<td>Up-regulation of cytokine/chemokine release; CCL5/RANTES induces pro-inflammatory profile in microglia; recruitment of immune cells to site of injury</td>
</tr>
<tr>
<td>ATP/P2 receptors</td>
<td>ATP stimulates IL-33 release from microglia pre-activated with PAMPs via TLRs</td>
<td>IL-33 binds to its receptor on mast cells and induces secretion of IL-6, IL-13 and monocyte chemoattractant protein 1 which, in turn could modulate microglia activity</td>
</tr>
<tr>
<td>Proteinase-activated receptor 2 (PAR2)</td>
<td>Mast cell tryptase cleaves/activates PAR2 on microglia, resulting in P2X7 receptor up-regulation and BDNF release</td>
<td>IL-6 and TNF-α from microglia can up-regulate mast cell expression of PAR2, which can result in mast cell activation and TNF-α release</td>
</tr>
<tr>
<td>CXCR4/CXCL12</td>
<td>Promotes microglia migration and activation; CXCR4/CXCL12 are both up-regulated in hypoxia/ischaemia</td>
<td>CXCR4 acts as mast cell chemotaxin</td>
</tr>
<tr>
<td>C5a receptor (C5aR)</td>
<td>C5aR up-regulated upon microglia activation; C5a peptide released in neuroinflammation; cross-talk between C5a and TLR4</td>
<td>C5aR up-regulated upon activation; a strong mast cell chemoattractant signal towards C5a peptide; cross-talk between C5a and TLR4</td>
</tr>
<tr>
<td>CD40/CD40L</td>
<td>Astrocytes display enhanced expression of CD40 – cross-talk with CD40L leads to production of inflammatory cytokines; astrocyte-derived cytokines/chemokines trigger mast cell degranulation</td>
<td>Display enhanced surface expression of CD40L respectively – cross-talk with CD40 leads to production of inflammatory cytokines</td>
</tr>
</tbody>
</table>

BDNF, brain-derived neurotrophic factor; IL, interleukin; PAMPs, pathogen-associate molecular patterns; PAR, proteinase-activated receptor; TLR, Toll-like receptor; TNF-α, tumour necrosis factor-α. [Modified from Skaper et al.95 (Table 1), Copyright (2012), with permission from the Federation of American Societies for Experimental Biology].
enzyme converts \(N\)-palmitoyl-phosphatidyl-ethanolamine into PEA. In the mammalian brain, NAEs are hydrolysed by: (i) fatty acid amide hydrolase in the endoplasmic reticulum, which breaks down NAEs into the corresponding fatty acid and ethanolamine;\(^{122}\) (ii) lysosomal NAE-hydrolysing acid amidase (NAAA) (Fig. 2).\(^{133}\) NAAA is found mainly in macrophages, where it hydrolyses NAEs with less than 18 carbon atoms, i.e. PEA, but not \(N\)-oleoylethanolamine and \(N\)-stearoylethanolamine. In contrast, fatty acid amide hydrolase hydrolys all three NAEs.

Molecules like PEA may, conceivably, function to maintain cellular homeostasis when faced with external stressors provoking, for example, inflammation.\(^{134}\) In fact, PEA is produced/hydrolysed by microglia and mast cells,\(^{135,136}\) it down-modulates mast cell activation,\(^{137}\) and controls microglial cell behaviours.\(^{138,139}\) Tissue levels of PEA are elevated in brain areas involved in nociception and in spinal cord following neuropathic pain induction,\(^{140}\) as well as conditions associated with pain development\(^{138,141}\) and in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck–shoulder pain (Table 3).\(^{142}\) The above observations suggest that PEA maintains cellular homeostasis by acting as mediator of resolution of inflammatory processes (Fig. 3). A corollary to this idea...

<table>
<thead>
<tr>
<th>Disease; tissue or body fluid</th>
<th>Change</th>
<th>Main finding</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic relapsing experimental allergic encephalomyelitis; spinal cord</td>
<td>↑</td>
<td>Two-fold increase</td>
<td>143</td>
</tr>
<tr>
<td>Experimental acute stroke; striatal and cortical infarced hemisphere</td>
<td>↑</td>
<td>25-fold increase compared with contralateral (non-infarcted) areas</td>
<td>144</td>
</tr>
<tr>
<td>Experimental focal cerebral ischaemia; ischaemic cerebral cortex</td>
<td>↑</td>
<td>25-fold increase compared with sham-operated animals, at 24 hr post-focal cerebral ischaemia</td>
<td>138</td>
</tr>
<tr>
<td>Cerebral ischaemia in man; penumbral tissue surrounding the primary ischaemic lesion (microdialysis study)</td>
<td>↑</td>
<td>Significantly increased levels within the first day after ischaemia</td>
<td>145</td>
</tr>
<tr>
<td>Chronic migraine or probable chronic migraine and probable analgesic-overuse headache; cerebrospinal fluid</td>
<td>↑</td>
<td>Significantly higher levels in the two patient groups (without significant difference between them) compared with control subjects</td>
<td>146</td>
</tr>
<tr>
<td>Chronic widespread pain and chronic neck–shoulder pain in women; microdialysis dialysate of the trapezius</td>
<td>↑</td>
<td>Significantly higher levels compared to healthy subjects, and correlation with pain intensity</td>
<td>142</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Model</th>
<th>Action</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compression model of spinal cord trauma in mice</td>
<td>Reduces spinal inflammation/tissue injury, ameliorates recovery of motor limb function</td>
<td>147,148</td>
</tr>
<tr>
<td></td>
<td>Limits mast cell infiltration and activation; reduces activation of microglia and astrocytes</td>
<td></td>
</tr>
<tr>
<td>Traumatic brain injury in mice</td>
<td>Reduces edema and infarct size</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>Improves neurobehavioural functions</td>
<td></td>
</tr>
<tr>
<td>MPTP mouse model of Parkinson’s disease</td>
<td>Protects against MPTP-induced neurotoxicity, microglial and astrocyte activation, and functional deficits</td>
<td>150</td>
</tr>
<tr>
<td>Stroke (middle cerebral artery occlusion in rats)</td>
<td>Reduces oedema and infarct size</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td>Improves neurobehavioural functions</td>
<td></td>
</tr>
<tr>
<td>(\beta)-Amyloid peptide injection in rat brain</td>
<td>Counteracts reactive gliosis</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>Reduces behaviour impairments</td>
<td></td>
</tr>
<tr>
<td>Chronic constriction injury in sciatic nerve</td>
<td>Anti-allodynic and anti-hyperalgesic effects</td>
<td>153–155</td>
</tr>
<tr>
<td></td>
<td>Reduces mast cell activation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preservation of nerve structural integrity</td>
<td></td>
</tr>
<tr>
<td>Acute inflammation (formalin, dextran, carrageenan injection in rat hindpaw)</td>
<td>Reduces mast cell activation, tissue oedema, inflammatory/mechanical hyperalgesia</td>
<td>156–161</td>
</tr>
<tr>
<td>WAG/Rij rat model of absence epilepsy</td>
<td>Anti-epileptic action</td>
<td>162</td>
</tr>
</tbody>
</table>

MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

© 2013 John Wiley & Sons Ltd. *Immunology*, **141**, 314–327
Figure 3. Palmitoylethanolamide (PEA) treatment reduces activation of astrocytes induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injection. Western blot analysis showed a significant expression of glial fibrillary acidic protein (GFAP) in the substantia nigra. PEA treatment significantly reduced the activation of astrocytes after MPTP injection. The relative expression of the protein band (~47 000 molecular weight) was standardized for densitometric analysis to β-actin levels, and reported as mean ± SEM from n = 3 or n = 6 brains for each group. * * * P < 0.001 versus sham, ****P < 0.001 versus MPTP + vehicle. Modified from Esposito et al. (2013, Immunology). Is an open-access article distributed under the terms of the Creative Commons Attribution License.

is that pathological situations may arise in which endogenous PEA levels are inadequate to deal with the ensuing insult. In these cases, exogenous administration to effectively ‘top up’ the body’s own supply may be a therapeutically viable approach. Indeed, a growing number of studies demonstrate the validity of such; these are briefly summarized in Table 4. A more detailed discussion is outside the scope of the review, and will be covered elsewhere (Skaper S.D., unpublished data). Importantly, PEA has no adverse effects at pharmacologically relevant doses.

As NAAA preferentially hydrolysces PEA, inhibition of its degradation represents a complementary therapeutic approach to treat inflammation. A number of selective NAAA inhibitors have been described to date,163–165 these dampen responses induced by inflammatory stimuli in vivo and in vitro, and elevate PEA levels in vitro as well.163 The most recently identified compound, 1-[(2-biphenyl-4-yl)ethyl-carbonyl] pyrrolidine, is a reversible and competitive NAAA inhibitor; it reduces mRNA expression levels of inducible nitric oxide synthase and IL-6 and increases intracellular PEA levels in mouse macrophages upon lipo-poly saccharide-induced inflammation.166

The numerous preclinical studies have encouraged clinical trials of PEA, mainly in the area of chronic and neuropathic pain. PEA reportedly improved myelinated-fibre nociceptive activity of other endogenous compounds by potentiating their affinity for a receptor or by inhibiting their metabolic degradation.175 Anandamide is a candidate molecule, as it possesses anti-inflammatory and anti-nociceptive effects. Anandamide and its congeners like PEA have in common the transient receptor potential vanilloid type 1 (TRPV1) receptor. The TRPV1 receptor, a non-selective cation channel expressed in small diameter sensory neurons, is activated by noxious heat, low pH and capsaicin. Anandamide itself is a TRPV1 receptor agonist, and PEA enhances anandamide stimulation of the human TRPV1 receptor in a cannabinoid CB2 receptor antagonist-sensitive fashion (although PEA shows no appreciable affinity for either CB1 or CB2 receptors) – which could be interpreted as PEA acting indirectly by potentiating anandamide actions.157 Mast cells177 and microglia178 reportedly express TRPV1 receptors.

### Concluding remarks
Neuroinflammatory disorders are conditions where immune responses damage components of the nervous system (Karolinska Institute, 2013; www.ki.se). Inflammatory effectors derive from the innate and adaptive immune systems, as well as glia within the CNS. Microglia, in particular, act as sensors for disturbed brain tissue homeostasis and accumulate locally in response to neuronal cell injury or entry of foreign material in the brain.179 Few studies until now have been directed to resident brain cell types capable of mounting immediate
host responses in the brain and meninges. Mast cells are effector cells of the innate immune system, and represent the ‘first responders’ to injury rather than microglia.\textsuperscript{51} Mast degranulation/mediator release is very rapid, while longer lasting activation elaborates de novo formed mediators. Mast cell degranulation does not result in cell demise; rather, mast cells are stable, multiple-use cells capable of surviving and delivering several consecutive hits.\textsuperscript{180}

Research to-date has largely focused on detrimental effects of neuroinflammation in association with psychiatric and neurodegenerative diseases, as well as neuropathic pain. Yet, we know little of glial and mast cell changes in human chronic pain – unequivocal demonstration that glial and mast cell activation occurs in hypersensitized patients remains an important gap. We lack also systematic studies that provide a correlation between the magnitude of glial and/or mast cell markers in cerebrospinal fluid or spinal tissue and the intensity of pain in patients.

Today’s armamentarium to combat neuropathic pain (antidepressants, anticonvulsants, sodium channel blockers, glutamate receptor antagonists, opioids) treats the symptoms but not the underlying pathophysiology.

Further, they provide at best transient relief in only a fraction of neuropathic pain patients and can produce serious CNS side effects. Agents like cromolyn, which stabilize mast cells, suppress development of hyperalgesia but do not affect microglia. Microglial inhibitors (e.g. minocycline) commonly used in pain models rely on their anti-inflammatory properties but may suffer from issues such as non-selectivity in targeting one cell population, as well as the risk of acute or cumulative toxicity. Incomplete understanding of mechanisms underlying the induction and maintenance of neuropathic pain has hindered more effective treatments, including elucidating the role of mast cells and how they might interact with microglia.

Clearly, much remains to be learned about signalling mechanisms that regulate neuroinflammation. One may envision the CNS neuron being subjected to ‘assault’ by a microglia–astrocyte–mast cell network, as a result of inadequate regulation of these non-neuronal cells because of excessive and/or persistent exogenous and/or endogenous stimuli, and/or an inadequate cellular inhibitory capacity (Fig. 4). Targeting endogenous regulators of neuroinflammation may therefore prove to be a viable strategy for affecting a diverse array of nervous system disorders. Within this context, the capacity of PEA to modulate the protective responses of animals during inflammation and pain led to the hypothesis that endogenous PEA may be a component of the complex homeostatic system controlling the basal threshold of both inflammation and pain. The production of PEA during inflammatory conditions supports this role, and emerging data that selective inhibition of PEA degradation is anti-inflammatory provides more direct evidence for the involvement of PEA in the control of pain and inflammation. It also leads one to ponder if we are not missing important therapeutic avenues by studying glia and mast cells in isolation from each other. Future studies should investigate the role of mast cells in inflammatory diseases as a network, which requires a critical examination of specific tissue localization, function and dynamic interaction with endogenous cells.

**Disclosures**

The authors declare no conflicts of interest.

**References**

Gilfillan AM, Austin SJ, Metcalfe DD. Mast cell biology: introduction and overview.

Silverman AJ, Sutherland AK, Wilhelm M, Silver R. Mast cells migrate from blood to

Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. Elevated mast cell tryp-

Appel SH, Zhao W, Beers DR, Henkel JS. The microglial

Medic N, Lorenzon P, Vita F, Trevisan E, Marchioli A, Soranzo MR, Fabbretti E, Za-

Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R. Brain mast cells link the immune sys-

Rosano C, Marsland AL, Gianaros PJ. Maintaining brain health by monitoring inflam-

Carson MJ. Microglia as liaisons between the immune and central nervous systems.

DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation

Wei F, Dubner R, Ren K. Glial


Lery D, Kainz V, Burstein R, Strassman AM. Mast cell degranulation distinctly acti-
vates trigemino-cerebral and lumbar spinal pain pathways and elicits widespread tactile

Koda H, Mizumura K. Stimulation to mechanical stimulation by inflammatory medi-

Leal-Berumen I, Conlon P, Marshall JS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipo-

Miyatake T, Xiao W, Kawamura M, Yuge O, Bennett GJ. Systemic glucocorticoid ther-


Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins


Ghosh A, Boya A, Liu X et al. Selective inhibition of NF-κB activation prevents dopa-


Jensen TS, Baron X, Hannjak M, Kalso E, Loover JD, Rizc A, Treede R. A new defi-

González-Scarrán F, Rablach G. Microglia as mediators of inflammatory and degener-

Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in


Rosano C, Marland AL, Gianuzzi PF. Maintaining brain health by monitoring inflam-


Carson MJ. Microglia as liaisons between the immune and central nervous systems.


Gao Y, Ji R.R. Chemokines, neuronal-glia interactions, and central processing of neu-

Engler H, Doenlen R, Engler A et al. Acute amygdaloid response to systemic inflam-


Wardlaw AJ, Sloof R, Cromwell O, Kay AR. Platelet-activating factor: a potent che-


Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Thoebardcs TC. Elevated mast cell try-


Medic N, Lorenzon P, Vita F, Trevissen E, Marchioli A, Soranzo MR, Fabbretti E, Za-


Wei F, Fuhner R, Ren K. Glial-cytokine-neuronal interactions underlying the mecha-

Mast cells, glia and neuroinflammation

65 Hall ED, Oostvra EM, Gurney ME. Relationship of microglial and astrogliotic activation to disease onset and progression in a transgenic model of familial ALS. GLIA 1998; 23:249–56.
68 Fiala M, Chattopadhyay M, La Cava A et al. IL-17A is increased in the serum and in spinal cord C1D and mast cells of ALS patients. J Neuroinflammation 2010; 7:76.
REVIEW SERIES ON IMMUNE RESPONSES IN NEURODEGENERATIVE DISEASES

S. D. Skaper et al.